Insight Molecular Diagnostics (IMDX) Gross Profit (2020 - 2026)

Insight Molecular Diagnostics has reported Gross Profit for 7 years, with the latest figure at $15000.0 in Q1 2026.

• Quarterly Gross Profit fell 98.87% year-over-year to $15000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (down 50.5% YoY) and the FY2025 annual result came in at $2.3 million, up 210.54% from the prior year.
• Gross Profit slipped to $15000.0 in Q1 2026 per IMDX's latest filing, from $496000.0 in the prior quarter.
• Over five years, Gross Profit peaked at $1.3 million in Q1 2025 and troughed at -$269000.0 in Q3 2022.
• A 5-year average of $203529.4 and a median of $50000.0 in 2024 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2023 and 2025: Gross Profit plunged 333.33% in 2023, then soared 2844.44% in 2025.
• Over 5 years, Gross Profit stood at -$27000.0 in 2022, then plunged by 333.33% to -$117000.0 in 2023, then jumped by 608.55% to $595000.0 in 2024, then slipped by 16.64% to $496000.0 in 2025, then slumped by 96.98% to $15000.0 in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $15000.0, $496000.0, and $139000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.